This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Dec;7(12):671.

doi: 10.1038/nrclinonc.2010.177.

Improved survival in second-line advanced prostate cancer treated with cabazitaxel

No authors listed

PMID: 21542197
DOI: 10.1038/nrclinonc.2010.177

Comment

Improved survival in second-line advanced prostate cancer treated with cabazitaxel

No authors listed. Nat Rev Clin Oncol. 2010 Dec.

. 2010 Dec;7(12):671.

doi: 10.1038/nrclinonc.2010.177.

PMID: 21542197
DOI: 10.1038/nrclinonc.2010.177

No abstract available

PubMed Disclaimer

Comment on

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. de Bono JS, et al. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X. Lancet. 2010. PMID: 20888992 Clinical Trial.

References

1. Lancet. 2010 Oct 2;376(9747):1147-54 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database